Pharma 4.0: Taking CDMO factories by storm

Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.

New modalities hog the limelight

Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.

Net-zero pledge: CDMOs go greener

A number of CDMOs are accelerating their environmental drive as sustainability goals become one of the most urgent business strategies facing pharma companies today.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details